Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912081294> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2912081294 endingPage "381" @default.
- W2912081294 startingPage "381" @default.
- W2912081294 abstract "381 Background: No established second-line treatment (2L) is available for patients (pts) with advanced biliary tract cancer (ABC) failing gemcitabine/platinum first-line chemotherapy (CT). However, 20-40% of pts are offered 2L CT in daily practice. We evaluated the impact of clinical and biochemical parameters on survival of ABC in order to identify factors aiding in 2L treatment selection. Methods: Medical records of consecutive ABC pts treated with 2L CT between 2005 and 2018 at the Modena Cancer Centre were reviewed. Log-rank test and multiple Cox proportional hazard regression were performed to assess the prognostic significance of covariates on OS. A prognostic score was developed from the multivariate model. Results: A total of 98 pts were identified and included in the analysis. Median (m) age was 63 years, 52% of pts were female, 75% had ECOG PS of 1-2. 72% of pts received first-line gemcitabine/platinum combination. In the 2L setting, 70% of pts received a doublet and the most common regimen was FOLFIRI (26%), followed by FOLFOX (20%) and fluoropyrimidine monotherapy (19%). Disease control rate was 39%, with 7% of objective responses. mOS and mPFS were 7.2 months and 3.5 months, respectively. At both univariate and multivariate analysis ECOG PS > 0 ( P= 0.002), peritoneum involvement ( P< 0.001), LDH > 430 UI/L ( P< 0.001), albumin < 3.5 g/dL ( P= 0.001), gamma-GT > 100 UI/L ( P= 0.001), PFS to first-line < 6 months ( P= 0.025), Na+ < 140 mEq/L ( P= 0.010), absolute lymphocyte count < 1000/uL ( P= 0.030) were significantly associated with shorter OS. By assigning to each of the 8 variables weight = 1, three different risk groups were identified: low-risk group (0-2 factors), intermediate-risk group (3-4 factors) and high-risk group (5-8 factors). mOS was 18, 9.4, and 2.9 months in the low-, intermediate-, and high-risk group, respectively ( P< 0.001). Conclusions: Our 2L study confirms the prognostic value of ECOG PS, PFS to first-line and peritoneal carcinomatosis, identifies novel biochemical prognosticators and proposes a readily-available and inexpensive score to risk stratify patients both in daily practice and clinical trials." @default.
- W2912081294 created "2019-02-21" @default.
- W2912081294 creator A5000225240 @default.
- W2912081294 creator A5008560824 @default.
- W2912081294 creator A5013636423 @default.
- W2912081294 creator A5021212136 @default.
- W2912081294 creator A5026433226 @default.
- W2912081294 creator A5039185748 @default.
- W2912081294 creator A5042028913 @default.
- W2912081294 creator A5052543756 @default.
- W2912081294 creator A5070358745 @default.
- W2912081294 creator A5070490189 @default.
- W2912081294 creator A5076874377 @default.
- W2912081294 creator A5081324410 @default.
- W2912081294 date "2019-02-01" @default.
- W2912081294 modified "2023-10-18" @default.
- W2912081294 title "Second-line chemotherapy in advanced biliary tract cancer: Who may benefit?" @default.
- W2912081294 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.381" @default.
- W2912081294 hasPublicationYear "2019" @default.
- W2912081294 type Work @default.
- W2912081294 sameAs 2912081294 @default.
- W2912081294 citedByCount "1" @default.
- W2912081294 countsByYear W29120812942022 @default.
- W2912081294 crossrefType "journal-article" @default.
- W2912081294 hasAuthorship W2912081294A5000225240 @default.
- W2912081294 hasAuthorship W2912081294A5008560824 @default.
- W2912081294 hasAuthorship W2912081294A5013636423 @default.
- W2912081294 hasAuthorship W2912081294A5021212136 @default.
- W2912081294 hasAuthorship W2912081294A5026433226 @default.
- W2912081294 hasAuthorship W2912081294A5039185748 @default.
- W2912081294 hasAuthorship W2912081294A5042028913 @default.
- W2912081294 hasAuthorship W2912081294A5052543756 @default.
- W2912081294 hasAuthorship W2912081294A5070358745 @default.
- W2912081294 hasAuthorship W2912081294A5070490189 @default.
- W2912081294 hasAuthorship W2912081294A5076874377 @default.
- W2912081294 hasAuthorship W2912081294A5081324410 @default.
- W2912081294 hasConcept C121608353 @default.
- W2912081294 hasConcept C126322002 @default.
- W2912081294 hasConcept C141071460 @default.
- W2912081294 hasConcept C143998085 @default.
- W2912081294 hasConcept C144301174 @default.
- W2912081294 hasConcept C207103383 @default.
- W2912081294 hasConcept C2776694085 @default.
- W2912081294 hasConcept C2776705615 @default.
- W2912081294 hasConcept C2778260052 @default.
- W2912081294 hasConcept C2778336483 @default.
- W2912081294 hasConcept C2780258809 @default.
- W2912081294 hasConcept C2780259306 @default.
- W2912081294 hasConcept C2780962732 @default.
- W2912081294 hasConcept C2781413609 @default.
- W2912081294 hasConcept C3017919176 @default.
- W2912081294 hasConcept C38180746 @default.
- W2912081294 hasConcept C44249647 @default.
- W2912081294 hasConcept C50382708 @default.
- W2912081294 hasConcept C526805850 @default.
- W2912081294 hasConcept C71924100 @default.
- W2912081294 hasConcept C90924648 @default.
- W2912081294 hasConceptScore W2912081294C121608353 @default.
- W2912081294 hasConceptScore W2912081294C126322002 @default.
- W2912081294 hasConceptScore W2912081294C141071460 @default.
- W2912081294 hasConceptScore W2912081294C143998085 @default.
- W2912081294 hasConceptScore W2912081294C144301174 @default.
- W2912081294 hasConceptScore W2912081294C207103383 @default.
- W2912081294 hasConceptScore W2912081294C2776694085 @default.
- W2912081294 hasConceptScore W2912081294C2776705615 @default.
- W2912081294 hasConceptScore W2912081294C2778260052 @default.
- W2912081294 hasConceptScore W2912081294C2778336483 @default.
- W2912081294 hasConceptScore W2912081294C2780258809 @default.
- W2912081294 hasConceptScore W2912081294C2780259306 @default.
- W2912081294 hasConceptScore W2912081294C2780962732 @default.
- W2912081294 hasConceptScore W2912081294C2781413609 @default.
- W2912081294 hasConceptScore W2912081294C3017919176 @default.
- W2912081294 hasConceptScore W2912081294C38180746 @default.
- W2912081294 hasConceptScore W2912081294C44249647 @default.
- W2912081294 hasConceptScore W2912081294C50382708 @default.
- W2912081294 hasConceptScore W2912081294C526805850 @default.
- W2912081294 hasConceptScore W2912081294C71924100 @default.
- W2912081294 hasConceptScore W2912081294C90924648 @default.
- W2912081294 hasIssue "4_suppl" @default.
- W2912081294 hasLocation W29120812941 @default.
- W2912081294 hasOpenAccess W2912081294 @default.
- W2912081294 hasPrimaryLocation W29120812941 @default.
- W2912081294 hasRelatedWork W1970056857 @default.
- W2912081294 hasRelatedWork W2115466023 @default.
- W2912081294 hasRelatedWork W2159303174 @default.
- W2912081294 hasRelatedWork W2321664903 @default.
- W2912081294 hasRelatedWork W2417717847 @default.
- W2912081294 hasRelatedWork W2912081294 @default.
- W2912081294 hasRelatedWork W3142433463 @default.
- W2912081294 hasRelatedWork W3199047607 @default.
- W2912081294 hasRelatedWork W4283777137 @default.
- W2912081294 hasRelatedWork W2382318593 @default.
- W2912081294 hasVolume "37" @default.
- W2912081294 isParatext "false" @default.
- W2912081294 isRetracted "false" @default.
- W2912081294 magId "2912081294" @default.
- W2912081294 workType "article" @default.